5 results about "Lauromacrogol" patented technology

The application belongs to the technical field of medicine, and relates to a medicine and instrument combination system for treating bromhidrosis by using a sclerosing agent and a multi-needle injection needle and application thereof. The medicine and instrument combination system is a medicine and instrument composition comprising a sclerosing agent and a disposable sterile injection needle. The sclerosing agent comprises one or more of polidocanol, lauromacrogol, sodium myristyl sulfate and sodium morrhuate. The disposable sterile injection needle is a nine-needle injection needle or a five-needle injection needle. The nine-needle injection needle or the five-needle injection needle has uniformly distributed needle heads and equal lengths of the needle heads. The medicine and instrument combination system can standardize injection of the sclerosing agent in the process of treating bromhidrosis, accurately control the dosage, control the curative effect, reduce adverse reactions and improve safety.

To provide a composition for external use excellent in low-temperature stability, especially capable of suppressing precipitation at low temperature.SOLUTION: The composition for external use includes an acyl methyl taurine salt and at least one precipitation inhibitor selected from lauromacrogol, lauric acid diethanolamide, and lauryl dimethylamine oxide.SELECTED DRAWING: None

The present application belongs to the field of pharmaceutical preparations, and particularly relates to an injectable temperature-sensitive gel foam sclerosing agent. The injectable temperature-sensitive gel foam sclerosing agent comprises lauromacrogol air foam and poloxamer 407, and is a new treatment strategy formed by combining the advantages of foam sclerosing agents and temperature-sensitive gels. In the process of compounding components, it is accidentally found that, under the synergistic effect of specific concentrations and components, lauromacrogol is the main foaming agent, poloxamer 407 is attached to the liquid film surface layer of the foam, the foam volume is basically unchanged, and the poloxamer 407 and lauromacrogol air foam are mutually synergistic, the stability of the foam is increased, and the action time of the drug at the lesion site is significantly prolonged.

Provided are: an inkjet ink for a solid preparation, the inkjet ink having exceptional dischargeability from a nozzle of an inkjet head when applied using an inkjet method; a solid preparation; and a method for producing a solid preparation. An inkjet ink for a solid preparation according to the present invention contains ethanol that serves as the main solvent, an active ingredient that is soluble in ethanol, and a viscosity adjuster that adjusts the viscosity of the inkjet ink for a solid preparation, the viscosity modifier being at least one selected from the group consisting of polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyethylene glycol sorbitan monooleate, polyethylene glycol, lauromacrogol, polyvinylpyrrolidone having a K value of 25 or lower, and shellac.

The invention relates to the technical field of medicine, and particularly discloses a foam hardening agent for treating low-flow-rate vascular malformation and a preparation method thereof, the foam hardening agent comprises a drug conjugate, a stabilizer, a water-soluble enhancer, foaming gas and an injection solvent; according to the drug conjugate, citric anhydride is bridged with lauromacrogol and bleomycin to form a covalent structure, so that the problems of non-uniform drug distribution and poor synergism during physical mixing are solved. The preparation method comprises the following steps: synthesizing a conjugate through esterification and amidation reactions, mixing the conjugate with auxiliary materials, and foaming through a Tesari method. The two drugs are bridged through the citric anhydride to form a conjugate which can be synergistically slowly released in a focus microenvironment, the curative effect is remarkably improved, meanwhile, the single drug dosage and toxic and side effects are reduced, and the foam preparation is high in stability, clear in development and suitable for precise interventional therapy guided by color ultrasound.